UroGen Pharma
URGN
85 hedge funds and large institutions have $137M invested in UroGen Pharma in 2023 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 10 closing their positions.
200% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 10
31% more funds holding
Funds holding: 65 → 85 (+20)
18% more capital invested
Capital invested by funds: $116M → $137M (+$20.7M)
2.92% more ownership
Funds ownership: 53.41% → 56.33% (+2.9%)
25% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 20
36% less call options, than puts
Call options by funds: $193K | Put options by funds: $300K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$8.97M |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.3M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.07M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.74M |
| 5 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
+$1.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
-$4.29M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.79M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.06M |
| 4 |
Millennium Management
New York
|
-$1.79M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.09M |
URGN Hedge Fund Activity: Q2 2023 in Review
85 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q2 2023, worth a combined $137M — up 18% from $116M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new URGN positions and 10 closed out — a net gain of 20 holders — while 15 added to existing stakes and 20 trimmed.
The largest buyer was BlackRock, adding an estimated $8.97M. The largest seller was Menora Mivtachim Holdings, cutting an estimated $4.29M.
- 85 institutional investors held UroGen Pharma (URGN) as of Q2 2023, up from 65 in Q1 2023.
- Funds reported $137M of UroGen Pharma stock for Q2 2023, up 18% quarter-over-quarter.
- 30 funds opened new UroGen Pharma positions in Q2 2023 and 10 closed out, a net change of +20 holders.
- The largest UroGen Pharma buyer in Q2 2023 was BlackRock, an estimated $8.97M added.
- The largest UroGen Pharma seller in Q2 2023 was Menora Mivtachim Holdings, an estimated $4.29M sold.
Based on aggregated 13F filings for Q2 2023.